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Abstract
Background: The blood-brain barrier (BBB) represents an insurmountable obstacle for most drugs thus obstructing an
effective treatment of many brain diseases. One solution for overcoming this barrier is a transport by binding of these drugs
to surface-modified nanoparticles. Especially apolipoprotein E (ApoE) appears to play a major role in the nanoparticle-
mediated drug transport across the BBB. However, at present the underlying mechanism is incompletely understood.
Methodology/Principal Findings: In this study, the uptake of the ApoE-modified nanoparticles into the brain capillary
endothelial cells was investigated to differentiate between active and passive uptake mechanism by flow cytometry and
confocal laser scanning microscopy. Furthermore, different in vitro co-incubation experiments were performed with
competing ligands of the respective receptor.
Conclusions/Significance: This study confirms an active endocytotic uptake mechanism and shows the involvement of low
density lipoprotein receptor family members, notably the low density lipoprotein receptor related protein, on the uptake of
the ApoE-modified nanoparticles into the brain capillary endothelial cells. This knowledge of the uptake mechanism of
ApoE-modified nanoparticles enables future developments to rationally create very specific and effective carriers to
overcome the blood-brain barrier.
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Introduction
The blood-brain barrier (BBB) is one of the most important and
impermeable physiological barriers in the organism. Its discovery
in 1885 goes back to Paul Ehrlich who showed in animal
experiments that after intravenous injection of trypan blue all
tissues with the exception of the brain and the spinal cord were
colored. Finally, after development of special electron microscopic
methods in the 60’s, the cerebral endothelial cells could be
identified as the cellular basis of the blood-brain barrier. These
brain capillary endothelial cells clearly differ from the endothelial
cells in the remaining body in both morphological and metabolic
properties. The endothelial cells of the BBB are connected by
Tight Junctions (TJ) [1], so that no fenestration between the cells
exists. The TJ close the intracellular space between the endothelial
cells and block the free diffusion of water-soluble polar substances.
Therefore, these cells create a high transendothelial electrical
resistance (TER) which yields in vivo values up to 2000 Vcm
2 [2,3].
In addition, the brain capillary endothelial cells possess an
increased number of mitochondria resulting in an increased
metabolic activity. The brain capillary endothelial cells are
surrounded by astrocytes, microglial cells, pericytes and nerve
ends. They play an essential part in the maintenance of the BBB
characteristics [4]. The BBB is involved in the regulation of the
constancy of the internal environment of the brain and maintains
an essential brain homeostasis. Only lipophilic and small
hydrophobic molecules can cross the BBB by diffusion. However,
many molecules falling into this category are not transported as
they are substrates for the very efficient efflux transporters such as
Pgp. Nevertheless, for some large molecules, peptides and proteins
receptor-mediated specific transport systems do exist [5,6]. As a
result of its properties, the BBB enables a protection of the brain
from the peripheral circulation and toxic substances but restricts
the transport of many therapeutically important drugs from the
blood into the brain [7], including anticancer drugs, Alzheimer
disease drugs, antibiotics, and a wide variety of central nervous
system (CNS)-active drugs. Because the BBB represents such an
insurmountable obstacle for most drugs an effective treatment of
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number of different strategies have been employed during the past
years to overcome this barrier. These strategies included the
osmotic opening of the tight junctions, the direct surgical
administration of drugs into the brain, and the use of prodrugs
or carrier systems like antibodies or liposomes [6,7,8,9]. Later on,
the use of nanotechnology came into play [10,11,12] and not only
liposomes but also solid lipid nanoparticles or different polymeric
nanoparticles [11] have successfully been used for the transport of
drugs across the BBB. Thus, it was possible to transport an
increasing number of nanoparticle-bound drugs including doxo-
rubicin [13,14,15], dalargin [11,16,17], loperamide [18,19,20],
and others [17,21,22] with different chemical properties and
therapeutic effects over the BBB. Moreover, these nanoparticles
have not only enhanced the transport of the drug into the brain
but also protected the active agents from enzymatic degradation
and were able to reduce side effects [23].
Some earlier work indicated that the binding of certain
apolipoproteins to the nanoparticles provides an optimal tool to
transport drugs over the BBB [19,24]. It could be shown, for
example, by means of two-dimensional polyacrylamid gel
electrophoresis that after injection into the blood stream,
apolipoprotein E (ApoE) was adsorbed onto the surface of
polysorbate 80-coated nanoparticles, which then could enter the
BBB [25,26]. Further studies verified a clear correlation between
the ApoE adsorption and the BBB passage. For instance, after
coating with polysorbate 80 and/or adsorption of apolipoprotein E
or B poly(butyl cyanoacrylate) nanoparticles were able to cross the
BBB in vivo and thus transported bound dalargin or loperamide
over this barrier [11,16,27]. The adsorption of other apolipopro-
teins except apolipoprotein A-I (ApoA-I) could not enable a
pharmacological effect of these substances [27,28]. Therefore, it
was hypothesized that these nanoparticles resemble endogenously
circulating lipoproteins [27,29,30] and are taken up by a receptor-
mediated pathway by the brain endothelial cells which express the
respective receptors [6,22,24,27,29,30,31]. The fact that nano-
particles made of human serum albumin with adsorbed or
covalently bound ApoE or ApoA-I can transport drugs over the
BBB [19,27,32], corroborated this assumption. Our other studies
showed a specific binding and uptake of ApoE- or ApoA-I-
modified human serum albumin nanoparticles on endothelial cells
and an entrance into the CNS by transcytosis and a delivery to
neurons [28,33].
However, up to now the exact mechanism of this nanoparticle
drug transport over the BBB was not fully known and the involved
receptor not identified. The present study aimed at the elucidation
of this uptake mechanism and the identification of this receptor
and was able to show in in vitro experiments the involvement of a
member of the low density lipoprotein receptor (LDLR) family,
namely the low density lipoprotein receptor related protein
(LRP1).
Materials and Methods
Nanoparticle preparation and characterization
Chemicals and Reagents. Human serum albumin (HSA,
fraction V, purity 96–99%, 65000 Da) as well as glutaraldehyde
25% solution was purchased from Sigma-Aldrich (Schnelldorf,
Germany). 2-Iminothiolane HCL (Traut’s reagent) and D-Salt
TM
Dextran Desalting columns were obtained from Pierce (Rockford,
USA). Recombinant apolipoprotein E3 (342000 Da) was
produced as described by Vogel et al. [34]. The crosslinker
Malhex-NH-PEG-COOSu (4800 Da) was purchased from RAPP
Polymere GmbH (Tu ¨bingen, Germany) while the M-SPA-5000
PEGylating reagent (5356 Da) was bought from Nektar
(Huntsville, USA). All other reagents and chemicals were
purchased from Merck (Darmstadt, Germany) in analytical grade.
Preparation of the HSA nanoparticles. Unmodified
human serum albumin (HSA) nanoparticles were produced
using a desolvation technique previously described by Langer
et al. [35] and Weber et al. [36,37]. For this purpose, 200 mg of
HSA were dissolved in 2 ml of a 10 mM NaCl solution. The
desolvation with 8 ml of ethanol 96% (drop wise addition with a
rate of 1 ml/min) was performed at a pH value of 8.0 under
constant stirring to form the nanoparticles. The particles were then
crosslinked with 200% glutaraldehyde (235 ml of an 8% solution)
to stabilize the colloid. Purification of the particles was achieved by
threefold centrifugation (8 min at 16100 g) and redispersion in
ultra-pure water.
Apolipoprotein E3 was attached to the surface of unmodified
HSA particles via a bifunctional Mal-PEG-NHS crosslinker
according to Michaelis et al. [38]. The poly (ethylene glycol)
crosslinker reacts with an amino group on the particle’s surface as
well as a thiol group introduced into the ApoE thus covalently
linking the two reaction partners. The thiolation of the ApoE was
achieved by incubating 1 mg of the apolipoprotein with a 50-fold
molar excess of 2-Iminothiolane HCL (Traut’s reagent) in
phosphate buffer at room temperature for 2 hours. The thiolated
ApoE was then purified using a D-Salt
TM Dextran Desalting
column and incubated with the crosslinker-activated nanoparticles
for 12 hours. The resulting ApoE-modified nanoparticles were
purified by threefold centrifugation and redispersion in ultra-pure
water.
As a control, HSA nanoparticles with poly (ethylene glycol)
(PEG) chains on their surface were prepared by linking mPEG-
SPA-5000 to the particle surface of unmodified HSA nanoparti-
cles. For this purpose 20 mg of HSA nanoparticles were incubated
with a 50-fold molar excess of mPEG-SPA-5000 (82.4 mg) in
phosphate buffer (pH 8.0) under constant shaking at room
temperature for one hour. The resulting PEGylated particles were
purified by threefold centrifugation and redispersion in ultra-pure
water.
Nanoparticle Characterization. The nanoparticle prepara-
tions were characterized concerning their size, polydispersity and zeta
potential using photon correlation spectroscopy (Zetasizer 3000 HSA,
Malvern, Germany). The dynamic light scattering measurements
were performed in aqueous suspension at 25uC and a measuring
angle of 90u. The concentration of the nanoparticle suspensions was
determined by microgravimetry and set to 10 mg/ml by diluting the
suspension with ultra-pure water.
Cell culture
For the in vitro cell culture studies the mouse brain endothelioma
cell line bEnd3 (LGC Promochem, Wesel, Germany) was used.
The cells were cultured at 37uC and 5% CO2 in DMEM high
glucose medium, supplemented with 10% fetal calf serum.
Cellular binding of the nanoparticles
For the cellular binding studies the bEnd3 cells were cultivated
on collagen IV-coated (Sigma-Aldrich, Steinheim, Germany) 24-
well plates until a post confluent monolayer had grown. Then, the
cells were incubated with 0.1 mg/ml of the different nanoparti-
culate formulations for 4 h (an established incubation time [33]) at
4uC and 37uC, respectively. Afterwards, the cells were washed
twice with PBS (Invitrogen, Karlsruhe, Germany), then trypsinized
and harvested. After washing with PBS and fixing with FACS-Fix
(10 g/l PFA and 8.5 g/l NaCl in PBS, pH 7.4) flow cytometry
(FACS) analysis was performed with 10,000 cells/sample, using
Uptake Mechanism of ApoE-Modified Nanoparticles
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Heidelberg, Germany). Due to a green autofluorescence of these
nanoparticles at 488/520 nm this FACS analysis was possible.
Cellular uptake and intracellular distribution of the
nanoparticles
Cellular uptake and intracellular distribution of the nanopar-
ticles were studied by confocal laser scanning microscopy (CLSM).
bEnd3 cells were cultured on collagen IV-coated glass slides and
treated with the different nanoparticle formulations for 4 h at
37uC. After this incubation the cells were washed twice with
serum-free medium and the cytosol was stained with CellTrack-
er
TM Red CMTPX (Invitrogen, Karlsruhe, Germany) as de-
scribed in the manufacturer instructions manual. Cells were fixed
with 0.5–1% PFA for 5–10 min. After fixation the cells were
embedded in Vectashield HardSet Mounting Medium containing
DAPI for cell nuclei staining. The CLSM study was performed
with an Axiovert 200 M microscope with a 510 NLO Meta device
(Zeiss, Jena, Germany), Ti:Sa femtosecond or an argon ion laser
and the LSM Image Examiner software. The green autofluores-
cence of the nanoparticles at 488/520 nm was used here.
Uptake mechanism study
Determination of the receptor state of the brain
endothelial cells. For the determination of the receptor state
flow cytometry analysis was also used. The bEnd3 cells were
cultivated on collagen IV-coated well plates until a post confluent
monolayer had grown. Then, the cells were permeabilized, fixed
and blocked with 5% goat serum (20 min, 4uC) before they were
incubated with the primary antibodies against the ApoE receptor
(ApoER) (Acris Antibodies GmbH, Herford, Germany), Megalin
(abcam, Cambridge, UK), LDLR (abcam, Cambridge, UK) or
LRP1 (Pietrzik et al. 2002 [39]) for 30 min at 4uC. The antibodies
were used in concentrations according to the manufactures’
instructions and more diluted, respectively. Afterwards, the cells
were washed with PBS and incubated with the corresponding
secondary antibody (Invitrogen, Karlsruhe, Germany) for 30 min
at 4uC. After washing with PBS and fixing with FACS-Fix (10 g/l
PFA and 8.5 g/l NaCl in PBS, pH 7.4) flow cytometry (FACS)
analysis was performed with 10,000 cells/sample, using
FACSCalibur and CellQuest Pro software. As an antibody
control the cells were incubated only with the secondary
antibody and also analyzed.
GST fusion proteins purification. LRP1 ligand binding
domains and RAP were subcloned into the pGEX-4T vector
(Amersham Pharmacia Biotech, Piscataway, New Jersey, USA).
Plasmids were transformed into Escherichia coli BL21 and protein
expression was induced by 1 mM IPTG (Roth, Karlsruhe,
Germany) for 4 h. After bacterial lysis in 3% sarkosyl buffer cell
debris were spun down at 14,000 rpm. The protein was pulled
down using glutathione-Sepharose beads (Amersham Biosciences,
Piscataway, New Jersey, USA) and eluted with a 10 mM
glutathione in 50 mM Tris solution pH 7.4.
Co-incubationexperiments. The co-incubationexperiments
were also performed by flow cytometry analysis. The bEnd3 cells
were cultivated on collagen IV-coated 24-well plates until a post
confluent monolayer had grown. Then, the cells were either
incubated with 0.1 mg/ml of the different nanoparticulate
formulations for 4 h at 37uC or co-incubated with 0.1 mg/ml of
the different nanoparticulate formulations and 1 mg/ml low density
lipoprotein (LDL) (Calbiochem/VWR, Darmstadt, Germany),
500 nM RAP+1 mg/ml LDL or 0.125 mg/ml LRP1 Dom II and
0.125 LRP1 Dom IV, respectively. Afterwards, the cells were
washed twice with PBS, then trypsinized and harvested. After
washing with PBS and fixing with FACS-Fix (10 g/l PFA and
8.5 g/l NaCl in PBS, pH 7.4) flow cytometry (FACS) analysis was
performed with 10,000 cells/sample, using FACSCalibur and
CellQuest Pro software. Due to a green autofluorescence of these
nanoparticles at 488/520 nm this FACS analysis was possible.
Results
Nanoparticle preparation and characterization
The human serum albumin-based nanoparticles were prepared
by a well-known desolvation technique previously described by
Langer et al. [35] and Weber et al. [36,37]. As summarized in
Table 1, the size of the ApoE-modified nanoparticles was
197.864.8 nm and the size of the PEGylated nanoparticles was
186.760.4 nm. The zeta potential of the nanoparticulate
formulations was between 226.667.5 and 242.566.3 and the
polydispersity index of all preparations was smaller than 0.1
demonstrating that monodisperse nanoparticle formulations have
been prepared. The high surface charge of both nanoparticle
preparations guaranties the colloidal stability of both systems. The
apolipoprotein molecules covalently bound on the particle surface
produced a higher zeta potential of the ApoE-modified nanopar-
ticles in comparison to the PEGylated nanoparticles due to the
higher number of chargeable groups.
Cellular binding of the nanoparticles
For the clarification of the uptake mechanism of ApoE-modified
nanoparticles,firstofall,thecellularbindingofthenanoparticleshad
to be proven by flow cytometry analysis. Therefore, the mouse brain
endothelioma cells bEnd3 were incubated either with the specific
ApoE-modified nanoparticles (NP-ApoE) or the unspecific PEGy-
lated control nanoparticles (NP-PEG) for 4 h at 37uCo ra t4 uC. The
histograms of both incubation temperatures are compared in
Figure 1. At 37uC a specific cellular binding of the ApoE-modified
nanoparticles could be detected by 36.7% of positive cells. In
comparison, the cellular binding of the control nanoparticles was
really low with 3.1% of positive cells demonstrating a marginal
unspecific binding. In contrast, at an incubation temperature of 4uC
almost no cellular binding of the unspecific and the specific
nanoparticles could be observed (less than 2% of positive cells).
Cellular uptake and subcellular distribution of the
nanoparticles
For studies concerning the cellular uptake and intracellular
distribution of the nanoparticles the confocal laser scanning
microscopy (CLSM) was used. The bEnd3 cells were incubated as
well with the unspecific PEGylated control nanoparticles as with
the specific ApoE-modified nanoparticles for 4 h at 37uC. In case
of the incubation with the specific ApoE-modified nanoparticles a
clear intracellular uptake and accumulation could be observed in
contrast to the unspecific control nanoparticles (Figure 2).
These findings argued for a receptor-mediated uptake of the
specific ApoE-modified nanoparticles. Thus, for clarification of the
Table 1. Nanoparticle characterization.
NP-PEG NP-ApoE
Particle diameter [nm] 186.760.4 197.864.8
Polydispersity 0.0360.03 0.0360.03
Zeta potential [mV] 226.667.5 242.566.3
doi:10.1371/journal.pone.0032568.t001
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located at the BBB were investigated.
Uptake mechanism study
Determination of the receptor state of the brain
endothelial cells. For the determination of the receptor state,
the bEnd3 cells were incubated with antibodies against the low
density lipoprotein receptor related protein (LRP1), the low
density lipoprotein receptor (LDLR), the ApoE-receptor (ApoER)
and Megalin in different concentrations. The bEnd3 cells
expressed all these receptors as indicated in Table 2. With
nearly 100% of positive cells the receptors Megalin, LRP1 and
LDLR were clearly more present than the ApoER with 21.1% of
positive cells.
The involvement of a certain receptor of the LDLR family then
was specifically investigated in different co-incubation experi-
ments.
Co-incubation experiments. In a first co-incubation
experiment the bEnd3 cells were incubated with the different
nanoparticulate formulations together with the low density
lipoprotein (LDL). Cells incubated solely with nanoparticles were
used as reference. At first, the specific targeting of the ApoE-
modified nanoparticles in contrast to the PEGylated control
nanoparticles could be observed (Table 3) corroborating the results
obtained in the binding study. The co-incubation of the
nanoparticles with LDL and the specific ApoE-modified
nanoparticles led to an increased number of positive cells with
an enhancement of 31.2% to 42.6% of positive cells whereas the
co-incubation with the unspecific nanoparticles showed only a
marginal enhancement of 3.3% to 4.5% of positive cells (Table 3).
Additional evidence for LDLR family member involvement in
ApoE nanoparticle uptake was generated by co-incubation
experiment using the receptor-associated protein (RAP). RAP
blocks all binding sites of most LDL receptor family members.
Therefore, the application of RAP to the tissue culture medium led
to a clear reduction of the number of positive cells (25.1% to 7.1%
of positive cells) binding ApoE-modified nanoparticles. In contrast,
the binding of the unspecific nanoparticles to the bEnd3 cells
increased slightly from 3.2% to 8.4% of positive cells (Table 4).
In a second co-incubation experiment the bEnd3 cells were
incubated with the different nanoparticles and purified soluble
fragments of the LRP1. These fragments express the binding
domains II and IV of LRP1, (LRP1 Dom II and LRP1 Dom IV)
Figure 1. Specific cellular binding of the ApoE-modified
nanoparticles studied by flow cytometry. bEnd3 cells were
incubated with ApoE-modified nanoparticles (NP-ApoE) or control
nanoparticles without ApoE modification (NP-PEG) for 4 h at 37uC and
4uC, respectively. Flow cytometry analysis was performed to quantify
their cellular binding. The data are shown as histograms of the FL1-H-
channel (autofluorescence of the nanoparticles) as well as in the table
with the analysis of the Y mean fluorescence and the percentage of
positive cells. Green: NP-ApoE, red: NP-PEG, blue: untreated control.
doi:10.1371/journal.pone.0032568.g001
Figure 2. Cellular uptake and intracellular distribution of the nanoparticles studied by CLSM: split of the fluorescence channels.
bEnd3 cells were incubated for 4 h with 0.1 mg/ml of the different nanoparticulate formulations at 376C. The green autofluorescence
of the nanoparticles was used for detection. The cytosol was stained in red with CellTracker
TM Red CMTPX, and the nucleus was stained in blue with
DAPI. Pictures were taken within inner sections of the cells. Untreated control cells: a) overlay of all fluorescence channels, b) display of the blue
nucleus channel, c) display of the green nanoparticle channel, d) display of the red cytosol channel. Cells with the unspecific control NP-PEG: e)
overlay of all fluorescence channels, f) display of the blue nucleus channel, g) display of the green nanoparticle channel, h) display of the red cytosol
channel. Cells with the specific NP-ApoE: i) overlay of all fluorescence channels, j) display of the blue nucleus channel, k) display of the green
nanoparticle channel, l) display of the red cytosol channel.
doi:10.1371/journal.pone.0032568.g002
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involved in the specific ApoE-mediated nanoparticle binding.
After exogenous addition to the culture medium both fragments
induced an inhibition of the specific nanoparticle binding to the
bEnd3 cells compared to the control experiment with 16.1% of
positive cells (Table 5). However the incubation with the LRP1
Dom IV caused a larger inhibitory effect (0.5% of positive cells)
than the LRP1 Dom II (10.4% of positive cells) indicating that this
domain might have a stronger effect on ApoE nanoparticle
binding.
Discussion
In our former mouse in vivo experiments ApoE-modified HSA-
based nanoparticles could be recovered in different brain regions
and neurons by transmission electron microscopy (TEM) images
already 15 minutes after their intravenous injection [33]. Howev-
er, the tight junctions in the brain regions remained intact,
indicating a specific endocytotic uptake of the ApoE-modified
nanoparticles at the luminal site of the endothelial cells and further
transcytosis into the brain at the abluminal site. In contrast, the
PEGylated nanoparticles could be detected only in minor amounts
in the endothelial cells and were not found at all in the residual
brain regions even 30 minutes after injection. This fact confirms
the unspecificity of the PEGylated nanoparticles. Corresponding in
vitro TEM investigations with the murine brain endothelioma cell
line bEnd3 and murine in vivo TEM investigations confirmed the
results that the nanoparticles were intracellular endocytosed by
formed pits. However, up to now the exact uptake mechanism of
these nanoparticles were not fully understood. Therefore, in order
to elucidate the nanoparticle transport mechanism over the BBB
ApoE-modified HSA-based nanoparticles and corresponding
PEGylated control nanoparticles were manufactured according
to an established process [35,36,37] and were tested on the former
established murine brain endothelioma cell line bEnd3. These cells
are suitable for studies addressing blood-brain barrier transport
mechanism according to Omidi et al. [40], who characterized the
bEnd3 cell line. The synthesized particles were in a size range of
about 200 nm and possessed a monodisperse particle size
distribution qualifying these particles for mechanism studies.
Furthermore, as already shown in our former publication [33],
these nanoparticles are not cytotoxic in the tested concentration
range.
First of all, clearly a specific cellular binding on the mouse brain
endothelioma cells bEnd3 was confirmed for the ApoE-modified
nanoparticles by flow cytometry, although at this stage the
corresponding receptor on the cellular side was not known. In
contrast, the PEGylated control nanoparticles showed only a
marginal cellular binding, which can be considered to be
unspecific. This experiment was performed at 37uC, a temperature
which is generally important for the maintenance of cellular
functions. However, when this experiment was conducted at 4uC
no specific cellular binding could be detected and the unspecific
binding part was reduced to the same level like the untreated cells.
At this temperature all active, energy consumptive transport
processes are stopped. These findings argued for an active
endocytotic uptake mechanism of the nanoparticles into the cells
and imply a receptor-mediated transcellular uptake pathway of the
nanoparticles over the endothelial cells into the brain.
Table 3. Co-incubation of bEnd3 cells with the different
nanoparticulate formulations and LDL.
NP incubation [%
positive cells]
NP+LDL co-incubation
[% positive cells]
NP-ApoE 31.2 42.6
NP-PEG 3.3 4.5
untreated control 1.7 1.1*
*: cells without NP incubation, with LDL.
One representative experiment out n.3 is shown.
doi:10.1371/journal.pone.0032568.t003
Table 2. Determination of the receptor state of the bEnd3
cells.
receptor
dilution of the
primary antibody % positive cells
Megalin C1 . 6
1:100 81.7
1:50 96.2
1:10 99.3
ApoER C1 . 6
1:100 3.2
1:20 10.0
1:10 21.1
LRP1 C1 . 5
1:1000 95.3
1:500 98.0
LDLR C1 . 5
1:70 97.9
C: control only with the secondary antibody.
doi:10.1371/journal.pone.0032568.t002
Table 4. Co-incubation of bEnd3 cells with the different
nanoparticulate formulations and LDL+RAP.
NP incubation [%
positive cells]
NP+LDL+RAP co-incubation
[% positive cells]
NP-ApoE 25.0 7.1
NP-PEG 3.2 8.4
untreated control 1.1 2.0*
*: cells without NP incubation, with LDL+RAP;
One representative experiment out n.3 is shown.
doi:10.1371/journal.pone.0032568.t004
Table 5. Co-incubation of bEnd3 cells with the different
nanoparticulate formulations and LRP1 Dom II and LRP1 Dom
IV, respectively.
NP incubation
[% positive cells]
NP+LRP1 Dom II
co-incubation
[% positive cells]
NP+LRP1 Dom IV
co-incubation
[% positive cells]
NP-ApoE 16.1 10.4 0.5
NP-PEG 1.4 2.2 1.6
One representative experiment out n=3 is shown.
doi:10.1371/journal.pone.0032568.t005
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subcellular distribution of the nanoparticulate formulations the
confocal laser scanning microscopy was used and a significant
intracellular accumulation could be observed. This result confirms
our former TEM investigations [33] where the intracellular
nanoparticle endocytosis by formed pits was shown. All these
findings supported former assumptions [27,29,30,32], that the
nanoparticulate transport of drugs over the BBB is a receptor-
mediated endocytotic process involving the selective binding
between ApoE and the respective receptor belonging to the
LDL receptor family. This assumption was further confirmed by
experiments with nanoparticles which were modified with an
ApoE-related nonsense sequence. These nanoparticles were
unable to transport bound drugs over the BBB [32].
Even though the incubation times and nanoparticle concentra-
tions are different in vivo and in vitro, it is realistic to assume that the
same receptors are involved in vivo and in vitro. Therefore, in the
scope of the present study further specific experiments concerning
the nanoparticulate transport mechanism of the ApoE-modified
HSA-based nanoparticles over the BBB were performed in in vitro
cell culture systems. As shown in this investigation the bEnd3 cells
express the LRP1, LDLR, Megalin and at lower level the ApoER.
Therefore, these cells were used for the transport mechanism
study. Moreover this receptor expression pattern of the bEnd3
cells indicated an involvement of the LDL receptor family by the
specific nanoparticle uptake and therefore the LRP1, a member of
the LDL receptor family [41], was especially investigated.
The co-incubation of the bEnd3 cells with the different
nanoparticulate formulations and LDL led to an enhanced uptake
of the specific ApoE-modified nanoparticles. The presence of the
LDL could induce a conformation change of the ApoE structure.
This may lead to an enhanced binding capacity of the ApoE to the
receptor since it is known that lipid-free ApoE does not bind to the
LDL receptor with high affinity and for the high affinity binding
an association with lipids such as phospholipids or lipoproteins is
required. [42,43,44]. Furthermore, the lipid composition has an
influence on the conformation of ApoE and therefore on the
receptor affinity [45].
Consequently, the enhanced specific uptake effect induced by
LDL was reversed by co-incubation with the receptor associated
protein RAP. In contrast, the cellular binding of the unspecific
nanoparticles was slightly enhanced. RAP is a protein that blocks
all binding sites on most receptors of the LDLR family and acts a
chaperon for LRP1 which is a member of this receptor group. It
enables the correct intracellular folding of the LRP1 through
binding on the ligand binding sites and prevents an early ligand-
receptor interaction [46,47]. In the in vitro culture, administration
of purified RAP blocks binding of LRLR ligands to receptors on
cellular surface. Consequently, the binding of ApoE attached to
the surface of the nanoparticles on the extracellular receptor in the
present experiments was also inhibited, demonstrating the
participation of the LDL receptor family in the nanoparticles’
uptake. With this experiment the specific nanoparticle binding on
cellular site could be inhibited.
Taking especially the LRP1 into account, further experiments
then focused on the question which binding domain of the LRP1 is
involved in the specific ApoE-mediated nanoparticle binding on
the cells. Therefore, the nanoparticles were co-incubated with
soluble fragments of the LRP1, which contained the main LRP1
binding domains II and IV, respectively [48]. In principle, with
both fragments an inhibition of the specific nanoparticle binding
could be induced in the present study whereby the incubation with
LRP1 Dom IV showed the stronger effect. It is a well-known fact
that both binding domains have been shown to bind numerous
LRP1 ligands [48]. With this experiment the specific nanoparticle
binding on nanoparticulate site could be inhibited. This
experiment provides first evidence that soluble LRP1 domains
can sequester ApoE-modified nanoparticles away from the cellular
bound receptor. Indicating that LRP1, which shows one of the
highest expression of all LDL receptors in bEnd3 cells, might act
as a transporter for ApoE-modified nanoparticles.
Within this experiment also a slight enhancement of the
unspecific binding rate could be verified. In general, it seems that
the cells enhance the unspecific nanoparticle uptake if the specific
uptake pathway is inhibited.
This data clearly demonstrates the participation of LDL
receptor family members, especially LRP1, on the specific
ApoE-mediated nanoparticle uptake on brain endothelial cells.
A participation of apolipoproteins in the transport of nanopar-
ticle-bound drugs over the BBB was already considered in earlier
experiments with polysorbate 80-coated poly(butyl cyanoacrylate)
(PBCA) nanoparticles. It was anticipated that these particles after
injection into the blood stream adsorb certain apolipoproteins on
their surface and as a result mimic circulating lipoproteins
[27,29,30] and thus could interact with the apolipoprotein
receptors of the BBB followed by their endo- and transcytosis.
The present studies confirmed these assumptions in that similar
uptake processes are taking place with the surfactant-coated and
apolipoprotein-adsorbed as with particles with covalently bound
apolipoprotein that was used here. In addition, the selective
neuronal uptake in in vitro primary cells was previously shown for
the polysorbate 80-coated PBCA nanoparticles, which could be
inhibited by an LDLR antibody [49]. Moreover, the employment
of apolipoprotein fractions containing only a binding sequence
appears to be sufficient [50,51,52,53].
Due to the understanding of the uptake and transport
mechanism of nanoparticulate formulations into the brain a
rational design of appropriate nanoparticles and the tailoring of
very specific and effective carriers seems to be feasible.
Author Contributions
Conceived and designed the experiments: S. Wagner FW CP JK HVB.
Performed the experiments: S. Wagner AZ S. Wien. Analyzed the data: S.
Wagner CP JK HVB. Contributed reagents/materials/analysis tools: ST
WM TV CP. Wrote the paper: S. Wagner AZ TV FW CP JK HVB.
References
1. Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug
development. NeuroRx 2: 3–14.
2. Crone C, Olesen SP (1982) Electrical resistance of brain microvascular
endothelium. Brain Res 241: 49–55.
3. Butt AM, Jones HC, Abbott NJ (1990) Electrical resistance across the blood-
brain barrier in anaesthetized rats: a developmental study. J Physiol 429: 47–62.
4. Rubin LL, Staddon JM (1999) The cell biology of the blood-brain barrier. Annu
Rev Neurosci 22: 11–28.
5. Begley DJ (2003) Understanding and circumventing the blood-brain barrier.
Acta Paediatr Suppl 92: 83–91.
6. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system:
the problems and the possibilities. Pharmacol Ther 104: 29–45.
7. Pardridge WM (1997) Drug delivery to the brain. J Cereb Blood Flow Metab 17:
713–731.
8. Pardridge WM (1988) Recent advances in blood-brain barrier transport. Annu
Rev Pharmacol Toxicol 28: 25–39.
Uptake Mechanism of ApoE-Modified Nanoparticles
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e325689. Neuwelt EA, Barnett PA In: Neuwelt EA, ed. Implications of the Blood-Brain
Barrier and its Manipulation. New York: Springer.
10. Calvo P, Gouritin B, Chacun H, Desmaele D, D’Angelo J, et al. (2001) Long-
circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for
brain delivery. Pharm Res 18: 1157–1166.
11. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA (1995) Passage of peptides
through the blood-brain barrier with colloidal polymer particles (nanoparticles).
Brain Res 674: 171–174.
12. Calvo P, Gouritin B, Brigger I, Lasmezas C, Deslys J, et al. (2001) PEGylated
polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases.
J Neurosci Methods 111: 151–155.
13. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, et al. (1999)
Significant transport of doxorubicin into the brain with polysorbate 80-coated
nanoparticles. Pharm Res 16: 1564–1569.
14. Hekmatara T, Bernreuther C, Khalansky AS, Theisen A, Weissenberger J, et al.
(2009) Efficient systemic therapy of rat glioblastoma by nanoparticle-bound
doxorubicin is due to antiangiogenic effects. Clin Neuropathol 28: 153–164.
15. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, et al. (2004)
Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles.
Int J Cancer 109: 759–767.
16. Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J (1995) Analgesic
activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-
coated poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 41:
44–48.
17. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA (1998) Nanoparticle technology
for delivery of drugs across the blood-brain barrier. J Pharm Sci 87: 1305–1307.
18. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, et al. (1997)
Delivery of loperamide across the blood-brain barrier with polysorbate 80-
coated polybutylcyanoacrylate nanoparticles. Pharm Res 14: 325–328.
19. Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, et al. (2007) Covalent
attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin
nanoparticles enables drug transport into the brain. J Control Release 118:
54–58.
20. Ulbrich K, Hekmatara T, Herbert E, Kreuter J (2009) Transferrin- and
transferrin-receptor-antibody-modified nanoparticles enable drug delivery across
the blood-brain barrier (BBB). Eur J Pharm Biopharm 71: 251–256.
21. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, et al. (1998)
Significant entry of tubocurarine into the brain of rats by adsorption to
polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain
perfusion study. J Microencapsul 15: 67–74.
22. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J (2000) Increase of the
duration of the anticonvulsive activity of a novel NMDA receptor antagonist
using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release
system. Eur J Pharm Biopharm 49: 103–109.
23. Rhaese S, von Briesen H, Rubsamen-Waigmann H, Kreuter J, Langer K (2003)
Human serum albumin-polyethylenimine nanoparticles for gene delivery.
J Control Release 92: 199–208.
24. Petri B, Bootz A, Khalansky A, Hekmatara T, Muller R, et al. (2007)
Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated
poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants.
J Control Release 117: 51–58.
25. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug
Deliv Rev 47: 65–81.
26. Lu ¨ck M (1997) Plasmaproteinadsorption als mo ¨glicher Schlu ¨sselfaktor fu ¨r eine
kontrollierte Arzneistoffapplikation mit partikula ¨ren Tra ¨gern. Berlin: Freie
Universita ¨t Berlin.
27. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, et al. (2002)
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the
blood-brain barrier. J Drug Target 10: 317–325.
28. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, et al. (2010) Human
serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-
brain barrier and enter the rodent brain. J Drug Target 18: 842–848.
29. Kreuter J (2006) Nanoparticles as drug delivery systems for the brain. In:
Benita S, ed. Microencapsulation: Methods and Industrial Application. New
York: Taylor and Francis. pp 689–706.
30. Kreuter J (2006) Nanoparticulate carriers for drug delivery to the brain. In:
Torchilin VP, ed. Nanoparticulates as Drug Carrier. London: Imperial College
Press. pp 527–547.
31. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, et al. (2003) Direct
evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles
deliver drugs to the CNS via specific mechanisms requiring prior binding of
drug to the nanoparticles. Pharm Res 20: 409–416.
32. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, et al. (2006)
Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances
drug transport into the brain. J Pharmacol Exp Ther 317: 1246–1253.
33. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, et al. (2009) Albumin
nanoparticles targeted with Apo E enter the CNS by transcytosis and are
delivered to neurones. J Control Release 137: 78–86.
34. Vogel T, Weisgraber KH, Zeevi MI, Ben-Artzi H, Levanon AZ, et al. (1985)
Human apolipoprotein E expression in Escherichia coli: structural and
functional identity of the bacterially produced protein with plasma apolipopro-
tein E. Proc Natl Acad Sci U S A 82: 8696–8700.
35. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, et al. (2003)
Optimization of the preparation process for human serum albumin (HSA)
nanoparticles. Int J Pharm 257: 169–180.
36. Weber C, Kreuter J, Langer K (2000) Desolvation process and surface
characteristics of HSA-nanoparticles. Int J Pharm 196: 197–200.
37. Weber C, Coester C, Kreuter J, Langer K (2000) Desolvation process and
surface characterisation of protein nanoparticles. Int J Pharm 194: 91–102.
38. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, et al. (2006)
Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances
drug transport into the brain. J Pharmacol Exp Ther 317: 1246–1253.
39. Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH (2002) The cytoplasmic
domain of the LDL receptor-related protein regulates multiple steps in APP
processing. EMBO J 21: 5691–5700.
40. Omidi Y, Campbell L, Barar J, Connell D, Akhtar S, et al. (2003) Evaluation of
the immortalised mouse brain capillary endothelial cell line, b.End3, as an in
vitro blood-brain barrier model for drug uptake and transport studies. Brain Res
990: 95–112.
41. Hertz J, Marchang P (2003) Coaxing the LDL receptor family into the fold. Cell
112: 289–292.
42. Hatters DM, Peters-Libeu CA, Weisgraber KH (2006) Apolipoprotein E
structure: insights into function. Trends Biochem Sci 31: 445–454.
43. Innerarity TL, Pitas RE, Mahley RW (1979) Binding of arginine-rich (E)
apoprotein after recombination with phospholipid vesicles to the low density
lipoprotein receptors of fibroblasts. J Biol Chem 254: 4186–4190.
44. Peters-Libeu CA, Newhouse Y, Hatters DM, Weisgraber KH (2006) Model of
biologically active apolipoprotein E bound to dipalmitoylphosphatidylcholine.
J Biol Chem 281: 1073–1079.
45. Weisgraber KH (1994) Apolipoprotein E: structure-function relationships. Adv
Protein Chem 45: 249–302.
46. Bu G, Geuze HJ, Strous GJ, Schwartz AL (1995) 39 kDa receptor-associated
protein is an ER resident protein and molecular chaperone for LDL receptor-
related protein. EMBO J 14: 2269–2280.
47. Bu G, Rennke S (1996) Receptor-associated protein is a folding chaperone for low
density lipoprotein receptor-related protein. J Biol Chem 271: 22218–22224.
48. Herz J, Strickland DK (2001) LRP: a multifunctional scavenger and signaling
receptor. J Clin Invest 108: 779–784.
49. Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM (2009) Functional
protein delivery into neurons using polymeric nanoparticles. J Biol Chem 284:
6972–6981.
50. Leupold E, Nikolenko H, Beyermann M, Dathe M (2008) Insight into the role of
HSPG in the cellular uptake of apolipoprotein E-derived peptide micelles and
liposomes. Biochim Biophys Acta 1778: 2781–2789.
51. Leupold E, Nikolenko H, Dathe M (2009) Apolipoprotein E peptide-modified
colloidal carriers: the design determines the mechanism of uptake in vascular
endothelial cells. Biochim Biophys Acta 1788: 442–449.
52. Sauer I, Dunay IR, Weisgraber K, Bienert M, Dathe M (2005) An
apolipoprotein E-derived peptide mediates uptake of sterically stabilized
liposomes into brain capillary endothelial cells. Biochemistry 44: 2021–2029.
53. Sauer I, Nikolenko H, Keller S, Abu Ajaj K, Bienert M, et al. (2006)
Dipalmitoylation of a cellular uptake-mediating apolipoprotein E-derived
peptide as a promising modification for stable anchorage in liposomal drug
carriers. Biochim Biophys Acta 1758: 552–561.
Uptake Mechanism of ApoE-Modified Nanoparticles
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32568